Search Results

Business

HORAMA Appoints Industry Veteran Ian Catchpole as Chief Scientific Officer

HORAMA, a clinical stage gene therapy company in ophthalmology, announced the appointment of Dr. Ian Catchpole as its Chief Scientific Officer.

May 4, 2020

·

3 min read

Business

HORAMA Appoints Life Sciences Veteran Benedikt Timmerman as New Chairman

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that seasoned life sciences executive Dr. Benedikt Timmerman is taking over as the firm’s new Chairman.

May 18, 2020

·

3 min read

Business

HORAMA Strengthens Its Management Team With the Appointment of Rodolphe Clerval as Chief Business Officer (CBO)

HORAMA, a clinical stage gene therapy company in ophthalmology, announced that Rodolphe Clerval has been appointed as Chief Business Officer.

March 11, 2020

·

3 min read

Business

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023

March 18, 2020

·

4 min read

Press Releases

Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board

September 4, 2024

·

4 min read

Horama Raises €19 Million in a Series B Financing Round

This fundraising was intended to finance the development of the HORA-PDE6B project, including the start of its clinical phase, which has just been authorised by the French regulatory bodies.

November 8, 2017

·

6 min read

Business

Horama Welcomes Three New Experts To Bolster Its Team

June 29, 2017

·

3 min read

Business

Jérôme Vailland Joins 4P-Pharma as Chief Financial Officer

4P-Pharma, a clinical-stage biotech based in Lille dedicated to developing curative therapies for serious untreated diseases, is thrilled to announce the appointment of Jérôme Vailland as Chief Financial Officer for 4P-Pharma and its subsidiaries.

March 14, 2024

·

3 min read

Horama Granted Orphan Drug Designation (ODD) In U.S. For Drug Candidate HORA-RLBP1

July 11, 2017

·

2 min read

Drug Development

Horama Granted Authorization To Conduct Phase I/II Clinical Study For HORA-PDE6B, In Retinitis Pigmentosa (RP)

October 11, 2017

·

2 min read